Cipla USA recalls Lanreotide Injection 120 mg/0.5 mL syringes due to particulate matter. Affected lots expire through 2027. Stop using if you have these specific lot numbers.
Presence of Particulate Matter.
Cipla USA is recalling Lanreotide Injection 120 mg/0.5 mL pre-filled syringes because they may contain particulate matter. This could cause serious injury if injected. Patients should stop using affected lots immediately.
Particulate matter in the injection could cause blockages or serious injury when injected into the body. This is a critical safety issue for patients receiving the medication.
Patients prescribed Lanreotide Injection by a doctor. Those with the specific lot numbers listed in the recall are most at risk.
Check the lot number on the syringe label. Affected lots include 4301954IR1 through 4401023IR1, expiring through March 2027.
Discard any Lanreotide Injection syringes with the affected lot numbers listed in the recall.
Particulate matter in the injection could cause blockages or serious injury when injected into the body.
Affected lots include 4301954IR1 through 4401023IR1, expiring through March 2027.
Yes, you should contact your doctor or healthcare provider to discuss alternative treatment options.
We’ve drafted a message you can send Cipla to request your refund or repair — edit it as you like.
Subject: Recall D-0290-2026 — Cipla Cipla Hello, I own a Cipla that is covered by recall D-0290-2026 from Cipla. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
